^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Glioblastoma
    Drug:Sitoiganap (ERC1671) (Immunostimulant)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    GlobeNewswire
    Title:

    ERC Granted FDA Fast Track Designation for Sitoiganap in Patients with Recurrent Glioblastoma

    Published date:
    07/26/2022
    Excerpt:
    ERC Belgium S.A. (ERC), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Sitoiganap® (Gliovac or ERC1671) ERC’s cell-based immunotherapy for the treatment of glioblastoma, the most aggressive form of brain cancer.